ClinConnect ClinConnect Logo
Search / Trial NCT06265246

Impact of Milk and Yogurt Supplementation on Bone Health, Body Composition, and Gut Microbiota in Canadian Young Adults

Launched by UNIVERSITY OF SASKATCHEWAN · Feb 9, 2024

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Probiotics Cultured Milk Products Milk Osteoporosis Obesity Gastrointestinal Microbiome Body Composition Yogurt

ClinConnect Summary

This clinical trial is studying how drinking milk and eating yogurt might affect bone health, body fat, and muscle mass in young adults in Canada. The researchers want to find out if yogurt, which contains beneficial bacteria, has a better effect on these health aspects compared to regular milk. They will be looking for participants aged 19 to 30 who don’t get enough calcium in their diet, specifically less than 1000 mg per day.

Eligible participants will be divided into three groups: one group will drink a specific amount of milk daily, another will eat a set amount of yogurt, and the third group will continue their usual diet without any changes. Over the course of 24 months, the researchers will measure various health indicators, such as bone strength and body composition. This trial aims to provide helpful information on how dairy products can support health and potentially guide future health recommendations. If you're interested and meet the criteria, this could be a great opportunity to contribute to important research!

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 19-30 years old
  • Dietary calcium intake below 1000mg/ day
  • living in the Saskatoon area (Saskatchewan, Canada)
  • Exclusion Criteria:
  • Calcium intake from both food and supplement above the estimated average requirement (EAR) for adults aged 19-30 years (\>800 mg/day)
  • Total dairy intake of more than 1 serving per day
  • Body mass index greater than to 30 kg/m2
  • Medical history of metabolic bone, liver, endocrine, connective tissue, and respiratory diseases, thyroid disorders, or cancer
  • Diagnosed cases with secondary osteoporosis due to hypoparathyroidism
  • Hormonal disorders or disturbances
  • Taking medications known to influence bone mass and density (e.g., steroids, diuretics, heparin, and cancer drugs)
  • Cow's milk allergy
  • Pregnant or lactating women, or those planning to conceive during the duration of the trial

About University Of Saskatchewan

The University of Saskatchewan is a leading research institution dedicated to advancing health sciences through innovative clinical trials and studies. With a commitment to improving patient outcomes, the university leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous and ethically sound research. By fostering collaborations among researchers, healthcare professionals, and industry partners, the University of Saskatchewan aims to translate scientific discoveries into practical applications that enhance healthcare delivery and contribute to the well-being of communities both locally and globally.

Locations

Saskatoon, Saskatchewan, Canada

Patients applied

TL

1 patients applied

Trial Officials

Hassan Vatanparast, MD, PhD

Principal Investigator

University of Saskatchewan

Phil Chilibeck, PhD

Principal Investigator

University of Saskatchewan

Sandra Clarke

Principal Investigator

Agriculture and Agri-Food Canada

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported